Considerations for the Nonclinical Safety Evaluation of Antibody-Drug Conjugates
1Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.
Abstract:
The targeted delivery of drugs by means of linking them to antibodies (Abs) to form antibody-drug conjugates (ADCs) has become an important approach in oncology and could potentially be used in other therapeutic areas. Targeted therapy is aimed at improving clinical efficacy while minimizing adverse reactions. The nonclinical safety assessment of ADCs presents several unique challenges involving the need to examine a complex molecule, each component of which can contribute to the effects observed, in appropriate animal models. Some considerations for the nonclinical safety evaluation of ADCs based on a literature review of ADCs in clinical development (currently or previously) are discussed.
Insights
Antibody-drug conjugates (ADCs) offer targeted cancer therapy with fewer side effects. Evaluating ADC safety in animals presents unique challenges due to their complex nature, requiring careful consideration in nonclinical studies.
Area of Science:
- Oncology
- Pharmacology
- Toxicology
Background:
- Antibody-drug conjugates (ADCs) represent a significant advancement in targeted therapy, particularly in oncology.
- ADCs aim to enhance therapeutic efficacy while reducing adverse reactions by linking antibodies to cytotoxic drugs.
- Their potential extends beyond oncology to other therapeutic areas.
Purpose of the Study:
- To discuss considerations for the nonclinical safety assessment of ADCs.
- To highlight the unique challenges in evaluating the safety of these complex molecules.
- To review ADCs currently or previously in clinical development.
Main Methods:
- Literature review of ADCs in clinical development.
- Analysis of safety assessment strategies for complex molecules.
- Examination of component contributions to observed effects in animal models.
Main Results:
- Nonclinical safety evaluation of ADCs faces unique challenges.
- Assessment requires examining complex molecules with multiple contributing components.
- Appropriate animal models are crucial for accurate safety evaluation.
Conclusions:
- The nonclinical safety assessment of ADCs requires specialized approaches.
- Understanding the interplay of antibody, linker, and payload is critical.
- Careful study design in relevant animal models is essential for predicting clinical safety.
More Related Videos
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
08:47Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
Published on: March 6, 2019
Related Concept Videos
01:14Phase II Conjugation Reactions: Overview
01:28Preclinical Development: Overview
01:28Drug Products: Biologics, Biosimilars and Interchangeables
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...